RxDoctor Payments Data

Stephen Bodi, PA

Physician Assistant · Cedar Park, TXNPI 1548225063

Payments from drug & device makers

$9,451in general payments, 2019–2025

Across 504 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$727
  • Novo Nordisk$707
  • AbbVie$705
  • Amgen$657
  • Lilly USA, LLC$631
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$9,39799%
  • Education$300%
  • Entertainment$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,451 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$32,745
Medicare patients
161
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$36,192
OzempicSemaglutide25$26,240
FarxigaDapagliflozin Propanediol22$25,318
SymbicortBudesonide/Formoterol Fumarate19$4,256
Rosuvastatin Calcium156$1,884
UnithroidLevothyroxine Sodium13$1,090
Lisinopril98$1,006
Pioglitazone Hcl56$936
Metformin Hcl ErMetformin Hcl69$899
Levothyroxine Sodium102$892
Tamsulosin Hcl48$819
Atorvastatin Calcium134$727
Amlodipine Besylate102$603
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide29$594
Gabapentin57$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$727$36,19224 claims
AstraZenecaFarxiga, Symbicort$1,136$29,57441 claims
Novo NordiskOzempic$707$26,24025 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$143$1,982115 claims
AbbVieSynthroid$705$46922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →